Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Slow movement at Gaza border after Israel reopens Rafah crossing
Air India checking fuel switches on its Boeing Dreamliners, memo says
Trump seeks $1 billion from Harvard University in damages
US to cut tariffs on India to 18%, India agrees to end Russian oil purchases
Son of Norway's crown princess stands trial for domestic violence
Israel reopens Gaza's Rafah border crossing to Egypt, with limits
US envoy Witkoff to visit Israel, meet Netanyahu, Israeli officials say
Russian drone strike kills 12 miners in Ukraine
